Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

Abstract Background Patients with a diagnosis of schizophrenia are at an increased risk for developing metabolic syndrome, which is associated with greater cardiovascular morbidity and mortality. Treatment with some commonly used antipsychotic medications may increase the risk of developing metaboli...

Full description

Bibliographic Details
Main Authors: Greg W. Mattingly, Peter M. Haddad, Michael Tocco, Jane Xu, Debra Phillips, Andrei Pikalov, Antony Loebel
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Psychiatry
Subjects:
Lurasidone
Antipsychotic agents
Schizophrenia
Adverse effects
Weight
Metabolic
Online Access:http://link.springer.com/article/10.1186/s12888-020-02523-1

Internet

http://link.springer.com/article/10.1186/s12888-020-02523-1

Similar Items